Francesca Barone compensation by year
Candel Therapeutics Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $362,192 | $413,005 | $443,303 | $483,312 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $155,400 | $110,534 | $0 | $0 |
| Option awards | $233,988 | $89,577 | $0 | $857,797 |
| Non-equity incentive | $144,522 | $80,560 | $269,119 | $206,427 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $12,200 | $13,200 | $13,800 | $14,000 |
| Total | $908,302 | $706,876 | $726,222 | $1,561,536 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Candel Therapeutics, Inc. DEF 14A filed April 29, 2026, accession 0001193125-26-191506, and prior-year filings.
How this page was built: the Candel Therapeutics, Inc. filed document, accession 0001193125-26-191506. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 2,292 | — | $4.12 |
| Option | 30,000 | — | $1.29 |
| Option | 1,667 | — | $4.06 |
| Option | 91,042 | — | $8.55 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Candel Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Candel Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Paul Peter Tak | Chief Executive Officer, President and Director | $5,344,561 |
| Francesca Barone · this page | Chief Scientific Officer | $1,561,536 |
| Charles Schoch | Chief Financial Officer, Treasurer and Secretary | $1,470,817 |
Francesca Barone's compensation dossier, Candel Therapeutics
You have read Francesca Barone's totals and holdings. The dossier adds each equity grant Candel Therapeutics disclosed for Francesca Barone and Candel Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Candel Therapeutics compensation record
free company briefThis page is one person within Candel Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Candel Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Candel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.